- Home
- NVNI vs AYTU Comparison
NVNI vs AYTU Comparison
Compare NVNI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- AYTU
- Stock Information
- Founded
- NVNI 2019
- AYTU N/A
- Country
- NVNI Brazil
- AYTU United States
- Employees
- NVNI N/A
- AYTU N/A
- Industry
- NVNI
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- NVNI
- AYTU Health Care
- Exchange
- NVNI Nasdaq
- AYTU Nasdaq
- Market Cap
- NVNI 10.4M
- AYTU 8.3M
- IPO Year
- NVNI N/A
- AYTU N/A
- Fundamental
- Price
- NVNI $0.22
- AYTU $1.09
- Analyst Decision
- NVNI
- AYTU
- Analyst Count
- NVNI 0
- AYTU 0
- Target Price
- NVNI N/A
- AYTU N/A
- AVG Volume (30 Days)
- NVNI 18.1M
- AYTU 37.1K
- Earning Date
- NVNI 05-07-2025
- AYTU 05-14-2025
- Dividend Yield
- NVNI N/A
- AYTU N/A
- EPS Growth
- NVNI N/A
- AYTU N/A
- EPS
- NVNI N/A
- AYTU N/A
- Revenue
- NVNI $23,558,620.00
- AYTU $77,232,000.00
- Revenue This Year
- NVNI $25.91
- AYTU N/A
- Revenue Next Year
- NVNI $17.52
- AYTU $8.14
- P/E Ratio
- NVNI N/A
- AYTU N/A
- Revenue Growth
- NVNI 38.59
- AYTU N/A
- 52 Week Low
- NVNI $0.17
- AYTU $1.15
- 52 Week High
- NVNI $12.19
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- NVNI 28.69
- AYTU 33.76
- Support Level
- NVNI $0.20
- AYTU $1.20
- Resistance Level
- NVNI $0.22
- AYTU $1.29
- Average True Range (ATR)
- NVNI 0.03
- AYTU 0.06
- MACD
- NVNI 0.11
- AYTU 0.00
- Stochastic Oscillator
- NVNI 25.00
- AYTU 0.00
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.